R. Amato, J. Jac, S. Giessinger, S. Saxena, and J. Willis, A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer, Cancer, vol.19, issue.11, pp.2438-2446, 2009.
DOI : 10.7326/0003-4819-144-7-200604040-00009

F. Andre, M. Campone, S. Hurvitz, L. Vittori, I. Pylvaenaeinen et al., Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab, Journal of Clinical Oncology, vol.26, issue.15_suppl, 2008.
DOI : 10.1200/jco.2008.26.15_suppl.1003

M. Atkins, M. Hidalgo, . Stadlerwm, T. Logan, J. Dutcher et al., Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma, Journal of Clinical Oncology, vol.22, issue.5, pp.909-918, 2004.
DOI : 10.1200/JCO.2004.08.185

A. Avadhani, K. Flaherty, M. Rosen, M. Veronese, K. Harlacker et al., A phase I trial of RAD001 in combination with cetuximab in patients with advanced solid tumors, J Clin Oncol, vol.25, p.14075, 2007.

R. Amato, J. Jaroslaw, S. Giessinger, S. Saxena, and J. Willis, A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer, Cancer, vol.19, issue.11, pp.2438-2484, 2009.
DOI : 10.7326/0003-4819-144-7-200604040-00009

J. Baselga, V. Semiglazov, P. Van-dam, A. Manikhas, M. Bellet et al., Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor???Positive Breast Cancer, Journal of Clinical Oncology, vol.27, issue.16, pp.2630-2637, 2009.
DOI : 10.1200/JCO.2008.18.8391

J. Bendell, D. George, A. Nixon, D. Yu, W. Petros et al., results of a phase I study of bevacizumab, everolimus and erlotinib in patients with advanced solid tumors, J Clin Oncol, vol.25, 2007.

L. Beretta, La rapamycine : identification d'une nouvelle voie de signalisation des facteurs de croissance, r??glant le d??but de la traduction, m??decine/sciences, vol.14, issue.5, pp.600-602, 1998.
DOI : 10.4267/10608/1099

A. Bodmer, M. Pelte, M. Verbist, and Y. Dietrich, Nouveautés thérapeutiques dans le cancer du rein : espoirs et questions. Revue médicale suisse, pp.1288-1296, 2007.

R. Broaddus, A phase II study of oral mammalian target of rapamycin(mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma, J Clin Oncol, vol.26, issue.5502, p.161, 2008.

K. Bullock, H. Hurwitz, H. Uronis, M. Morse, G. Blobe et al., Bevacizumab plus everolimus in refractory metastatic colorectal cancer, J Clin Oncol, vol.27, 2009.

P. Cen, A. Daleiden, G. Doshi, and R. Amato, A phase I study of everolimus plus sorafenib in patients with metastatic renal cell carcinoma (mRCC), J Clin Oncol, vol.27, p.16056, 2009.

S. Chan, M. Scheulen, S. Johnston, K. Mross, F. Cardoso et al., Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer, Journal of Clinical Oncology, vol.23, issue.23, pp.5314-5336, 2005.
DOI : 10.1200/JCO.2005.66.130

J. Chan, J. Vuky, L. Besaw, T. Beer, and C. Ryan, A phase II study of mammalian target of rapamycin (mTOR) inhibitor RAD001 plus imatinib mesylate in patients with previously treated advanced renal carcinoma, J Clin Oncol, vol.25, 2007.

S. Chang, P. Wen, T. Cloughesy, H. Greenberg, D. Schiff et al., Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme, Investigational New Drugs, vol.19, issue.4, pp.357-61, 2005.
DOI : 10.1016/S0002-9440(10)61702-6

S. Chang, J. Kuhn, K. Lamborn, T. Cloughesy, I. Robins et al., phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas, J Clin Oncol, vol.27, 2004.

S. Chawla, A. Tolcher, A. Staddon, S. Schuetze, D. Amato et al., Survival results with AP23573, a novel inhibitor, in patients with advanced soft tissue or bone sarcomas : a phase II trial, J Clin Oncol, vol.24, p.10076, 2006.

N. Colombo, S. Mcmeekin, P. Schwartz, J. Kotzka, C. Sessa et al., A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer, J Clin Oncol, vol.25, p.5516, 2007.

A. Cortot, J. Armand, and J. Soria, Les inhibiteurs de la voie PI3 kinase-AKT-mTOR, Bull Cancer, vol.93, pp.19-26, 2006.

C. Dreyer, S. Faivre, and R. E. , Voies de signalisation de la PI3K et de mTOR : perspectives de l'utilisation de la rapamycine et de ses dérivés en thérapie antitumorale ciblée, Bull Cancer, vol.hors série, pp.31-40, 2006.

C. Dreyer, M. Sablin, S. Faivre, and R. E. , Actualités sur la voie mTOR et ses inhibiteurs, Bull Cancer, vol.96, pp.87-94, 2009.

H. Dumez, P. Reichard, J. Blay, P. Schöffski, J. Morgan et al., A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinibresistant gastrointestinal stromal tumors (GIST), J Clin Oncol, vol.26, p.162, 2008.

J. Easton and P. Houghton, Therapeutic potential of target of rapamycin inhibitors, Expert Opinion on Therapeutic Targets, vol.11, issue.17, pp.551-564, 2004.
DOI : 10.1016/S1097-2765(03)00180-1

S. Ellard, K. Gelmon, and S. Chia, A randomized phase II study of two different schedules of RAD001 in patients with recurrent/ metastatic breast cancer, J Clin Oncol, vol.25, 2007.

S. Faivre, G. Kroemer, and R. E. , Current development of mTOR inhibitors as anticancer agents, Nature Reviews Drug Discovery, vol.10, issue.Abs. LBA 4, pp.671-688, 2006.
DOI : 10.1158/1078-0432.CCR-04-0035

M. Fouladi, F. Laningham, J. Wu, O. Shaughnessy, M. Molina et al., Phase I Study of Everolimus in Pediatric Patients With Refractory Solid Tumors, Journal of Clinical Oncology, vol.25, issue.30, pp.4806-4812, 2007.
DOI : 10.1200/JCO.2007.11.4017

M. Fury, E. Sherman, H. Stambuk, S. Haque, D. Lisa et al., Phase I study of everolimus + low dose weekly cisplatin for patients with advanced solid tumors: preliminary results, J Clin Oncol, vol.27, 2009.

E. Galanis, J. Buckner, M. Maurer, J. Kreisberg, K. Ballman et al., Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study, Journal of Clinical Oncology, vol.23, issue.23, pp.5294-304, 2005.
DOI : 10.1200/JCO.2005.23.622

S. Giessinger, R. Amato, J. Jac, S. Saxena, J. Willis et al., A phase I study with a daily regimen of the oral mTOR inhibitor RAD001 (Everolimus) plus sorafenib for patients with metastatic renal cell cancer (MRCC), Journal of Clinical Oncology, vol.26, issue.15_suppl, p.14603, 2008.
DOI : 10.1200/jco.2008.26.15_suppl.14603

R. Gunn and H. Hailes, Insights into the PI3-K-PKB-mTOR signalling pathway from small molecules, Journal of Chemical Biology, vol.3, issue.1-4, pp.49-62, 2008.
DOI : 10.4049/jimmunol.170.5.2647

A. Harzstark, J. Rosenberg, V. Weinberg, J. Sun, C. Ryan et al., A phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma, J Clin Oncol, vol.27, 2009.

N. Hay and N. Sonenberg, Upstream and downstream of mTOR, Genes & Development, vol.18, issue.16, pp.1926-1945, 2004.
DOI : 10.1101/gad.1212704

G. Hess, J. Romaguera, G. Verhoef, R. Herbrecht, M. Crump et al., Phase III study of patients with relapsed, refractory mantle cell lymphoma treated with temsirolimus compared with investigator???s choice therapy, Journal of Clinical Oncology, vol.26, issue.15_suppl, 2008.
DOI : 10.1200/jco.2008.26.15_suppl.8513

C. Hoban, A. Hoering, T. Synold, V. Chung, D. Gandara et al., Phase I evaluation of lapatinib and everolimus in patients with advanced malignancies: Southwest Oncology Group trial S0528, J Clin Oncol, vol.27, 2009.

L. Howard, K. Bullock, J. Bendell, H. Uronis, G. Vlahovic et al., Bevacizumab plus everolimus and panitumumab in refractory advanced solid tumors, J Clin Oncol, vol.27, pp.3551-163, 2009.

G. Hudes, Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.22, pp.2271-2281, 2007.
DOI : 10.1056/NEJMoa066838

K. Inoki, H. Ouyang, Y. Li, and K. Guan, Signaling by Target of Rapamycin Proteins in Cell Growth Control, Microbiology and Molecular Biology Reviews, vol.69, issue.1, pp.79-100, 2005.
DOI : 10.1128/MMBR.69.1.79-100.2005

J. Jac, S. Giessinger, M. Khan, J. Willis, S. Chiang et al., A phase II trial of RAD001 in patients with metastatic renal cell carcinoma, J Clin Oncol, vol.25, 2007.

J. Jac, R. Amato, S. Giessinger, S. Saxena, and J. Wilis, A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic renal cell carcinoma which has progressed on tyrosine kinase inhibition therapy, Journal of Clinical Oncology, vol.26, issue.15_suppl, 2008.
DOI : 10.1200/jco.2008.26.15_suppl.5113

P. Jonhston, S. Ansell, J. Colgan, T. Habermann, D. Inwards et al., Phase II trial of the oral of mTOR inhibitor everolimus for patients with relapsed or refractory lymphoma, J Clin Oncol, vol.25, 2007.

A. Kay, R. Motzer, R. Figlin, B. Escudier, S. Oudard et al., Updated data from a phase III randomised trial of everolimus versus PBO in metastatic renal cell carcinoma, Genitourinary Cancers Symposium, 2009.

F. Khuri, R. Harvey, N. Saba, T. Owonokoko, J. Kauh et al., Everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory NSCLC: a phase I study, J Clin Oncol, vol.27, 2009.

G. Kroog, D. Feldman, G. Kondagunta, M. Ginsberg, P. Fischer et al., Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma, J Clin Oncol, vol.27, 2009.

K. Kim, M. Davies, N. Papadopoulos, A. Bedikian, W. Hwu et al., Phase I/II study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma, J Clin Oncol, vol.27, p.9026, 2009.

I. Konings, J. Verweij, E. Wiemer, and S. Sleijfer, The Applicability of mTOR Inhibition in Solid Tumors, Current Cancer Drug Targets, vol.9, issue.3, pp.439-450, 2009.
DOI : 10.2174/156800909788166556

A. Kotsakis, A. Tarhini, D. Petro, R. Flaugh, G. Vallabhaneni et al., Phase II study of RAD001 in previously treated small cell lung cancer, J Clin Oncol, vol.27, 2009.

M. Kris, G. Riely, C. Azzoli, R. Heelan, L. Krug et al., Combined inhibition of mTOR and EGFR with everolimus and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: a phase II trial, J Clin Oncol, vol.25, p.7575, 2007.

A. Levy and L. Sauvin, Everolimus (RAD001) et tumeurs solides : le point en, Bull Cancer, vol.95, pp.1205-1211, 2008.

Y. Mamane, mTOR, translation initiation and cancer, Oncogene, vol.25, issue.48, pp.6416-6422, 2006.
DOI : 10.1038/sj.onc.1209495

URL : http://www.nature.com/onc/journal/v25/n48/pdf/1209888a.pdf

K. Margolin, J. Longmate, T. Baratta, T. Synold, S. Christensen et al., CCI-779 in metastatic melanoma, Cancer, vol.4, issue.5, pp.1045-1048, 2005.
DOI : 10.1200/JCO.2004.04.072

J. Moroney, R. Coleman, D. Hong, J. Wheler, C. Ng et al., A phase I trial of liposomal doxorubicin, bevacizumab and temsirolimus in advanced malignancy, J Clin Oncol, vol.27, 2009.

R. Motzer, G. Hudes, B. Curti, D. Mcdermott, B. Escudier et al., Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma, Journal of Clinical Oncology, vol.25, issue.25, pp.3958-3964, 2007.
DOI : 10.1200/JCO.2006.10.5916

R. Motzer, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, The Lancet, vol.372, issue.9637, pp.449-456, 2008.
DOI : 10.1016/S0140-6736(08)61039-9

S. Moulder, E. Rivera, J. Ensor, A. Gonzalez-angulo, M. Chrostofanilli et al., Phase I trial of escalating doses of weekly everolimus in combination with docetaxel for the treatment of metastatic breast cancer, J Clin Oncol, vol.27, p.1066, 2009.

K. Muro, N. Boku, Y. Yamada, T. Nishina, T. Doi et al., Multicenter phase II study of RAD001 for previously treated metastatic gastric cancer (MGC): Preliminary results, Journal of Clinical Oncology, vol.26, issue.15_suppl, p.4541, 2008.
DOI : 10.1200/jco.2008.26.15_suppl.4541

A. Naing, P. Lorusso, G. Mills, D. Berry, L. Doyle et al., Phase I study combining an IGFR inhibitor (IMC-A12) and an mTOR inhibitor (temsirolimus) in patients with solid tumors or lymphoma, J Clin Oncol, vol.27, 2009.

S. Okuno, M. Mahoney, H. Bailey, D. Adkins, W. Maples et al., A multicenter phase 2 consortium study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas, J Clin Oncol, vol.24, 2006.

T. Owonikoko, R. Stoller, D. Petro, R. Flaugh, P. Hershberger et al., Phase II study of RAD001 (Everolimus) in previously treated small cell lung cancer (SCLC), Journal of Clinical Oncology, vol.26, issue.15_suppl, 2008.
DOI : 10.1200/jco.2008.26.15_suppl.19017

A. Oza, L. Elit, J. Biagi, W. Chapman, M. Tsao et al., Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer, J Clin Oncol, vol.24, 2006.

A. Oza, L. Elit, D. Provencher, J. Biagi, L. Panasci et al., A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b, Journal of Clinical Oncology, vol.26, issue.15_suppl, pp.5516-165, 2008.
DOI : 10.1200/jco.2008.26.15_suppl.5516

A. Oza, C. Kollmannsberger, H. Hirte, S. Welch, L. Siu et al., Phase I study of temsirolimus, carboplatin and paclitaxel in patients with advanced solid tumors : NCIC CTG IND 179, 2009.

N. Pallet, P. Beaune, E. Thervet, C. Legendre, and D. Anglicheau, Inhibiteurs de mTOR : Des antiprolif??ratifs pl??iotropiques, m??decine/sciences, vol.22, issue.11, pp.947-952, 2006.
DOI : 10.1051/medsci/20062211947

K. Pandya, S. Dahlberg, M. Hidalgo, R. Cohen, M. Lee et al., A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding or Stable Disease after Induction Chemotherapy: A Trial of the Eastern Cooperative Oncology Group (E1500), Journal of Thoracic Oncology, vol.2, issue.11, pp.1036-1077, 2007.
DOI : 10.1097/JTO.0b013e318155a439

V. Papadimitrakopoulou, J. Soria, J. Douillard, G. Giaccone, J. Wolf et al., A phase II study of RAD001 monotherapy in patients with advanced non-small cell lung cancer failing prior platinium-based chemotherapy or prior chemotherapy and EGFR inhibitors, J Clin Oncol, vol.25, p.7589, 2007.

V. Papadimitrakopoulou, G. Blumenschein, N. Leighl, J. Bennouna, L. Soria et al., A phase1/2study investigating the combination of RAD001 (everolimus) and erlotinib as 2nd and 3rd line therapy in patients with advanced non-small cell lung cancer previously treated with chemotherapy: phase 1 results, J Clin Oncol, vol.26, 2008.

H. Pelz, G. Krekeler, L. Bergmann, J. Roigas, T. Steiner et al., Evaluation of safety, tolerability and activity: a registry for temsirolimus-treated patients with advanced or metastatic renal cell carcinoma in the usual health care setting, J Clin Oncol, vol.27, 2009.

E. Plimack, Y. Wong, V. Mehren, M. Malizzia, L. Roethke et al., A phase I study of temsirolimus and bryostatin in patients with metastatic renal cell carcinoma, J Clin Oncol, vol.27, 2009.

R. Rao, J. Allred, H. Windschitl, J. Maples, R. Mcwilliams et al., N0377 : Results of NCCTG phase II trial of the mTOR inhibitor RAD-001 in metastatic melanoma, J Clin Oncol, vol.25, 2007.

J. Robert, De la chimiothérapie classique à la chimiothérapie ciblée : les mécanismes de l'oncogenèse aux niveaux cellulaire et moléculaire, Bull Cancer, vol.hors série, pp.5-16, 2006.

J. Robert, Qu'est ce qu'une thérapeutique ciblée ? Le point de vue du biologiste, Bull Cancer, vol.94, pp.101-110, 2007.

J. Rosenberg, V. Weinberg, C. Claros, C. Ryan, A. Lin et al., Phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma, Journal of Clinical Oncology, vol.26, issue.15_suppl, p.5109, 2008.
DOI : 10.1200/jco.2008.26.15_suppl.5109

C. Ryan, J. Vuky, J. Chan, T. Beer, and M. Rothkopf, Phase II study of everolimus with imatinib in patients with previously-treated renal cell carcinoma (RCC), J Clin Oncol, vol.27, 2009.

J. Sarkaria, E. Galanis, W. Wu, C. Giannini, K. Jaeckle et al., NCCTG phase I trialof temsirolimus and temozolomide in combination with radiation therapy in newly diagnosed glioblastoma multiforme patients, J Clin Oncol, vol.27, 2009.

A. Schwandt, L. Wood, R. Bukowski, P. Elson, J. Garcia et al., Temsirolimus in metastatic renal cell carcinoma: safety and efficacy in patients previously treated with VEGF-targeted therapy, Genitourinary Cancers Symposium, 2009.

S. Sharma, T. Reid, S. Hoosen, C. Garrett, J. Beck et al., Phase I study of RAD001, cetuximab and irinotecan as second-line therapy in metastatic colorectal cancer, J Clin Oncol, vol.27, 2009.

B. Slomovitz, K. Lu, T. Johnston, M. Munsell, L. Ramondetta et al., A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC), Journal of Clinical Oncology, vol.26, issue.15_suppl, 2008.
DOI : 10.1200/jco.2008.26.15_suppl.5502

J. Spano, Qu'est ce qu'une thérapie ciblée ? Le point de vue du clinicien, Bull Canc, vol.94, pp.111-114, 2007.

S. Vignot, S. Faivre, D. Aguirre, and R. E. , mTOR-targeted therapy of cancer with rapamycin derivatives, Annals of Oncology, vol.16, issue.4, pp.525-537, 2005.
DOI : 10.1093/annonc/mdi113

P. Wen, T. Cloughesy, J. Kuhn, K. Lamborn, L. Abrey et al., phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma, J Clin Oncol, vol.27, 2006.

R. Whorf, J. Hainsworth, D. Spigel, D. Yardley, H. Burris et al., Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC), Journal of Clinical Oncology, vol.26, issue.15_suppl, 2008.
DOI : 10.1200/jco.2008.26.15_suppl.5010

B. Wolpin, A. Hezel, D. Ryan, T. Abrams, J. Meyerhardt et al., Phase II study of RAD001 in previously treated patients with metastatic pancreatic cancer, Journal of Clinical Oncology, vol.26, issue.15_suppl, p.4614, 2008.
DOI : 10.1200/jco.2008.26.15_suppl.4614

Y. Yamada, T. Doi, K. Muro, N. Boku, T. Nishina et al., Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer: main results, Gastointestinal Cancers Symposium, 2009.

J. Yao, A. Phan, D. Chang, R. Wolff, C. Jacobs et al., Phase II study of RAD001 and depot octreotide in advanced low grade neuroendocrine carcinoma, J Clin Oncol, vol.25, p.4503, 2007.

J. Yao, A. Phan, D. Chang, R. Wolff, K. Hess et al., Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study, Journal of Clinical Oncology, vol.26, issue.26, pp.4311-4318, 2008.
DOI : 10.1200/JCO.2008.16.7858

J. Yao, C. Lombard-bohas, E. Baudin, L. Kvols, P. Rougier et al., A phase II trial of daily oral RAD001 in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy, 2009.

E. Raymond, Le concept de cible en cancérologie, John Libbey Eurotext et AMGEN, 2008.